JCR Pharmaceuticals Co Ltd
TSE:4552
JCR Pharmaceuticals Co Ltd
Income from Continuing Operations
JCR Pharmaceuticals Co Ltd
Income from Continuing Operations Peer Comparison
Competitive Income from Continuing Operations Analysis
Latest Figures & CAGR of Competitors
Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
J
|
JCR Pharmaceuticals Co Ltd
TSE:4552
|
Income from Continuing Operations
¥5.4B
|
CAGR 3-Years
9%
|
CAGR 5-Years
17%
|
CAGR 10-Years
13%
|
Takeda Pharmaceutical Co Ltd
TSE:4502
|
Income from Continuing Operations
¥178.3B
|
CAGR 3-Years
0%
|
CAGR 5-Years
10%
|
CAGR 10-Years
2%
|
|
Daiichi Sankyo Co Ltd
TSE:4568
|
Income from Continuing Operations
¥186.6B
|
CAGR 3-Years
38%
|
CAGR 5-Years
23%
|
CAGR 10-Years
6%
|
|
Otsuka Holdings Co Ltd
TSE:4578
|
Income from Continuing Operations
¥141.7B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
11%
|
CAGR 10-Years
-1%
|
|
Chugai Pharmaceutical Co Ltd
TSE:4519
|
Income from Continuing Operations
¥325.5B
|
CAGR 3-Years
15%
|
CAGR 5-Years
28%
|
CAGR 10-Years
20%
|
|
Astellas Pharma Inc
TSE:4503
|
Income from Continuing Operations
¥37.3B
|
CAGR 3-Years
-35%
|
CAGR 5-Years
-29%
|
CAGR 10-Years
-9%
|
See Also
What is JCR Pharmaceuticals Co Ltd's Income from Continuing Operations?
Income from Continuing Operations
5.4B
JPY
Based on the financial report for Dec 31, 2023, JCR Pharmaceuticals Co Ltd's Income from Continuing Operations amounts to 5.4B JPY.
What is JCR Pharmaceuticals Co Ltd's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
13%
Over the last year, the Income from Continuing Operations growth was 4%. The average annual Income from Continuing Operations growth rates for JCR Pharmaceuticals Co Ltd have been 9% over the past three years , 17% over the past five years , and 13% over the past ten years .